Online inquiry

IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3465MR)

This product GTTS-WQ3465MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3465MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3853MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ12505MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ14320MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ14743MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ9318MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMP-321
GTTS-WQ7679MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ3422MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ9045MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMC-18F1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW